naftopidil has been researched along with Cancer of Ovary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Florent, R | 1 |
| Weiswald, LB | 1 |
| Lambert, B | 1 |
| Brotin, E | 1 |
| Abeilard, E | 1 |
| Louis, MH | 1 |
| Babin, G | 1 |
| Poulain, L | 1 |
| N'Diaye, M | 1 |
1 other study available for naftopidil and Cancer of Ovary
| Article | Year |
|---|---|
Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib.
Topics: Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Female; Humans; Mitogen-Activated | 2020 |